(Q37899341)

25 August 2017

1 reference

title

Intracellular defenses against HIV, viral evasion and novel therapeutic approaches (English)

1 reference

25 August 2017

0 references

Robert A Lever

1

1 reference

PubMed ID

21741003

25 August 2017

Andrew M L Lever

series ordinal

2

1 reference

25 August 2017

1 June 2011

1 reference

Journal of the Formosan Medical Association

25 August 2017

1 reference

25 August 2017

110

1 reference

25 August 2017

350-362

1 reference

25 August 2017

6

1 reference

Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Transmission of HTLV-III Infection from Human Plasma to Chimpanzees: An Animal Model for AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Animal models of AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Restriction of HIV-1 (subtype B) replication at the entry step in rhesus macaque cells

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Early replication block of human immunodeficiency virus type 1 in monkey cells

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Restriction of lentivirus in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

A dominant block to HIV-1 replication at reverse transcription in simian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Restriction of multiple divergent retroviruses by Lv1 and Ref1

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Trim36/Haprin plays a critical role in the arrangement of somites during Xenopus embryogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

TRIM family proteins: retroviral restriction and antiviral defence

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

TRIM45, a novel human RBCC/TRIM protein, inhibits transcriptional activities of ElK-1 and AP-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

The tripartite motif family identifies cell compartments

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

A retrovirus restriction factor TRIM5alpha is transcriptionally regulated by interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Implication of TRIM alpha and TRIMCyp in interferon-induced anti-retroviral restriction activities

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

TRIM/RBCC, a novel class of 'single protein RING finger' E3 ubiquitin ligases

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

BTBD1 and BTBD2 colocalize to cytoplasmic bodies with the RBCC/tripartite motif protein, TRIM5delta

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Functional replacement of the RING, B-box 2, and coiled-coil domains of tripartite motif 5alpha (TRIM5alpha) by heterologous TRIM domains

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

A B-box 2 surface patch important for TRIM5alpha self-association, capsid binding avidity, and retrovirus restriction

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Characterization of TRIM5alpha trimerization and its contribution to human immunodeficiency virus capsid binding

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Unique features of TRIM5alpha among closely related human TRIM family members

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Interfering residues narrow the spectrum of MLV restriction by human TRIM5alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

All three variable regions of the TRIM5alpha B30.2 domain can contribute to the specificity of retrovirus restriction

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Structural and functional insights into the B30.2/SPRY domain.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Proteasomal degradation of TRIM5alpha during retrovirus restriction

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

The control of viral infection by tripartite motif proteins and cyclophilin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Contribution of RING domain to retrovirus restriction by TRIM5alpha depends on combination of host and virus

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

High-frequency persistence of an impaired allele of the retroviral defense gene TRIM5alpha in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

An HIV-1 resistance polymorphism in TRIM5α gene among Chinese intravenous drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Potent lentiviral restriction by a synthetic feline TRIM5 cyclophilin A fusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

HIV-1 accessory proteins--ensuring viral survival in a hostile environment

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

APOBEC3G encapsidation into HIV-1 virions: which RNA is it?

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

The requirement for Vif of SIVmac is cell-type dependent

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

APOBEC-mediated interference with hepadnavirus production

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Guidelines for naming nonprimate APOBEC3 genes and proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

The HIV 'A' (sor) gene product is essential for virus infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Evidence for a newly discovered cellular anti-HIV-1 phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Hypermutation of HIV-1 DNA in the Absence of the Vif Protein

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

DNA deamination mediates innate immunity to retroviral infection

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Cytidine deamination of retroviral DNA by diverse APOBEC proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Inhibition of hepatitis B virus replication by APOBEC3G.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

APOBEC3 proteins inhibit human LINE-1 retrotransposition

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

APOBEC-mediated viral restriction: not simply editing?

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both Its Translation and Intracellular Stability

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

APOBEC3G inhibits elongation of HIV-1 reverse transcripts

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Complementary function of the two catalytic domains of APOBEC3G.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

APOBEC3G subunits self-associate via the C-terminal deaminase domain

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

The Vif Protein of HIV Triggers Degradation of the Human Antiretroviral DNA Deaminase APOBEC3G

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3)

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Population stratification of a common APOBEC gene deletion polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

APOBEC3B deletion and risk of HIV-1 acquisition

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Small-molecule inhibition of HIV-1 Vif.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Effects of IFN alpha on late stages of HIV-1 replication cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Function of human immunodeficiency virus type 1 Vpu protein in various cell types.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Quantitative membrane proteomics reveals new cellular targets of viral immune modulators

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Tetherin inhibits HIV-1 release by directly tethering virions to cells

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

CD4 binding affinity determines human immunodeficiency virus type 1-induced alpha interferon production in plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Bone Marrow Stromal Cell Antigen 2 Is a Specific Marker of Type I IFN-Producing Cells in the Naive Mouse, but a Promiscuous Cell Surface Antigen following IFN Stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Tetherin restricts productive HIV-1 cell-to-cell transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Nef proteins from simian immunodeficiency viruses are tetherin antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960053-3

7 January 2021

10.1016/S0929-6646(11)60053-3

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21741003